What is Greenwich Lifesciences Inc?
, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 282.56M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 0 | 57,300 shares $97k |
| 6-9months | 0 | 0 |
| 9-12months | 0 | 620,600 shares $379k |